DNA methylation as a molecular biomarker in gastric cancer

Tomomitsu Tahara, Tomiyasu Arisawa

研究成果: Review article

41 引用 (Scopus)

抄録

DNA methylation plays a significant role in gastric carcinogenesis. The CpG island methylator phenotype (CIMP) characterizes distinct subtypes of gastric cancer (GC) and the relationship between specific methylation patterns and clinicopathological features has been evaluated. Altered DNA methylation is also observed in Helicobacter pylori-infected gastric mucosa, and its potential utility for GC risk estimation has been suggested. The ability to detect small amounts of methylated DNA among tissues allows us to use DNA methylation as a molecular biomarker in GC in a variety of samples, including serum, plasma and gastric washes. The DNA methylation status of nontargeted tissue, particularly blood, has been associated with predisposition to GC. We focus on the recent development of DNA methylation-based biomarkers in GC.

元の言語English
ページ(範囲)475-486
ページ数12
ジャーナルEpigenomics
7
発行部数3
DOI
出版物ステータスPublished - 01-01-2015

Fingerprint

DNA Methylation
Stomach Neoplasms
Biomarkers
Stomach
CpG Islands
Gastric Mucosa
Helicobacter pylori
Methylation
Carcinogenesis
Phenotype
DNA
Serum

All Science Journal Classification (ASJC) codes

  • Genetics
  • Cancer Research

これを引用

Tahara, Tomomitsu ; Arisawa, Tomiyasu. / DNA methylation as a molecular biomarker in gastric cancer. :: Epigenomics. 2015 ; 巻 7, 番号 3. pp. 475-486.
@article{f7188cfc45394e5784b973b4b000464e,
title = "DNA methylation as a molecular biomarker in gastric cancer",
abstract = "DNA methylation plays a significant role in gastric carcinogenesis. The CpG island methylator phenotype (CIMP) characterizes distinct subtypes of gastric cancer (GC) and the relationship between specific methylation patterns and clinicopathological features has been evaluated. Altered DNA methylation is also observed in Helicobacter pylori-infected gastric mucosa, and its potential utility for GC risk estimation has been suggested. The ability to detect small amounts of methylated DNA among tissues allows us to use DNA methylation as a molecular biomarker in GC in a variety of samples, including serum, plasma and gastric washes. The DNA methylation status of nontargeted tissue, particularly blood, has been associated with predisposition to GC. We focus on the recent development of DNA methylation-based biomarkers in GC.",
author = "Tomomitsu Tahara and Tomiyasu Arisawa",
year = "2015",
month = "1",
day = "1",
doi = "10.2217/epi.15.4",
language = "English",
volume = "7",
pages = "475--486",
journal = "Epigenomics",
issn = "1750-1911",
publisher = "Future Medicine Ltd.",
number = "3",

}

DNA methylation as a molecular biomarker in gastric cancer. / Tahara, Tomomitsu; Arisawa, Tomiyasu.

:: Epigenomics, 巻 7, 番号 3, 01.01.2015, p. 475-486.

研究成果: Review article

TY - JOUR

T1 - DNA methylation as a molecular biomarker in gastric cancer

AU - Tahara, Tomomitsu

AU - Arisawa, Tomiyasu

PY - 2015/1/1

Y1 - 2015/1/1

N2 - DNA methylation plays a significant role in gastric carcinogenesis. The CpG island methylator phenotype (CIMP) characterizes distinct subtypes of gastric cancer (GC) and the relationship between specific methylation patterns and clinicopathological features has been evaluated. Altered DNA methylation is also observed in Helicobacter pylori-infected gastric mucosa, and its potential utility for GC risk estimation has been suggested. The ability to detect small amounts of methylated DNA among tissues allows us to use DNA methylation as a molecular biomarker in GC in a variety of samples, including serum, plasma and gastric washes. The DNA methylation status of nontargeted tissue, particularly blood, has been associated with predisposition to GC. We focus on the recent development of DNA methylation-based biomarkers in GC.

AB - DNA methylation plays a significant role in gastric carcinogenesis. The CpG island methylator phenotype (CIMP) characterizes distinct subtypes of gastric cancer (GC) and the relationship between specific methylation patterns and clinicopathological features has been evaluated. Altered DNA methylation is also observed in Helicobacter pylori-infected gastric mucosa, and its potential utility for GC risk estimation has been suggested. The ability to detect small amounts of methylated DNA among tissues allows us to use DNA methylation as a molecular biomarker in GC in a variety of samples, including serum, plasma and gastric washes. The DNA methylation status of nontargeted tissue, particularly blood, has been associated with predisposition to GC. We focus on the recent development of DNA methylation-based biomarkers in GC.

UR - http://www.scopus.com/inward/record.url?scp=84931360022&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931360022&partnerID=8YFLogxK

U2 - 10.2217/epi.15.4

DO - 10.2217/epi.15.4

M3 - Review article

C2 - 26077432

AN - SCOPUS:84931360022

VL - 7

SP - 475

EP - 486

JO - Epigenomics

JF - Epigenomics

SN - 1750-1911

IS - 3

ER -